127 related articles for article (PubMed ID: 8666124)
1. Menorest: a clinical overview.
Wren B
Int J Gynaecol Obstet; 1996 Mar; 52 Suppl 1():S27-9. PubMed ID: 8666124
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of Menorest in two positive-controlled studies.
Pornel B
Eur J Obstet Gynecol Reprod Biol; 1996 Apr; 64 Suppl():S35-7. PubMed ID: 8732472
[TBL] [Abstract][Full Text] [Related]
3. New trends in transdermal technologies: development of the skin patch, Menorest.
Marty JP
Int J Gynaecol Obstet; 1996 Mar; 52 Suppl 1():S17-20. PubMed ID: 8666122
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study.
Pornel B; Genazzani AR; Costes D; Dain MP; Lelann L; Vandepol C
Maturitas; 1995 Nov; 22(3):207-18. PubMed ID: 8746878
[TBL] [Abstract][Full Text] [Related]
5. HRT and long-term compliance: the efficacy and safety of Menorest.
Studd J; Panay N; Zamblera D; Leather AT
Int J Gynaecol Obstet; 1996 Mar; 52 Suppl 1():S21-5. PubMed ID: 8666123
[TBL] [Abstract][Full Text] [Related]
6. A double-blind comparative study of Estraderm and Premarin in the amelioration of postmenopausal symptoms.
Place VA; Powers M; Darley PE; Schenkel L; Good WR
Am J Obstet Gynecol; 1985 Aug; 152(8):1092-9. PubMed ID: 2992278
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerance of Menorest compared to Premarin in the treatment of postmenopausal women. A randomised, multicentre, double-blind, double-dummy study.
Studd JW; McCarthy K; Zamblera D; Burger HG; Silberberg S; Wren B; Dain MP; Le Lann L; Vandepol C
Maturitas; 1995 Sep; 22(2):105-14. PubMed ID: 8538478
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy.
Gordon SF
Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 2):998-1004. PubMed ID: 7573298
[TBL] [Abstract][Full Text] [Related]
9. [Basic principles of hormone replacement therapy in the postmenopause].
Dören M
Ther Umsch; 2000 Oct; 57(10):628-34. PubMed ID: 11081374
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of Menorest (50 mikrog/day) compared to Premarin 0.625 mg in the treatment of menopausal symptoms and the prevention of bone loss, in menopausal women. A single-center, comparative, randomized, double-blind, double-dummy study.
Studd JW; MacCarthy K; Zamblera D; Dain MP
Scand J Rheumatol Suppl; 1996; 103():89-90. PubMed ID: 8966497
[TBL] [Abstract][Full Text] [Related]
11. 17Beta-estradiol delivered by three different matrix patches 50 microg/day: a three way cross-over study in 21 postmenopausal women.
Rohr UD; Nauert C; Stehle B
Maturitas; 1999 Sep; 33(1):45-58. PubMed ID: 10585173
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the local tolerability and adhesion of a new matrix system (Menorest) for estradiol delivery with an established transdermal membrane system (Estraderm TTS).
Erianne JA; Winter L
Maturitas; 1997 Mar; 26(2):95-101. PubMed ID: 9089558
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of transdermal estradiol.
Judd H
Am J Obstet Gynecol; 1987 May; 156(5):1326-31. PubMed ID: 3034062
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of climacteric syndrome using Estraderm TTS and premarin in a comparative study].
Leodolter S; Sainz H; Moll-Schüler I; Mach R
Gynakol Geburtshilfliche Rundsch; 1992; 32(4):201-4. PubMed ID: 1337708
[TBL] [Abstract][Full Text] [Related]
15. Menorest: technical development and pharmacokinetic profile.
Marty JP
Eur J Obstet Gynecol Reprod Biol; 1996 Apr; 64 Suppl():S29-33. PubMed ID: 8732471
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with transdermal estradiol in the treatment of the climacteric.
Utian WH
Minerva Endocrinol; 1989; 14(1):45-8. PubMed ID: 2543895
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of transdermal with oral hormone substitution: a multicenter study with a new matrix patch].
Sajtos B; Herold J; Winkler UH; Schindler AE
Zentralbl Gynakol; 1995; 117(10):524-30. PubMed ID: 7491835
[TBL] [Abstract][Full Text] [Related]
18. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies.
Rovati LC; Schmid K; Giacovelli G; Bonn M; Setnikar I; Wolff F; Genazzani AR
Arzneimittelforschung; 1999 Nov; 49(11):933-43. PubMed ID: 10604047
[TBL] [Abstract][Full Text] [Related]
19. [Clinical effectiveness of a new matrix plaster: an overview].
Schindler AE; Schindler EM
Zentralbl Gynakol; 1995; 117(10):508-9. PubMed ID: 7491832
[No Abstract] [Full Text] [Related]
20. Estrogen replacement therapy and the estraderm transdermal system.
Youngkin EQ
Nurse Pract; 1990 May; 15(5):19-26, 31. PubMed ID: 2342664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
